Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
Status:
Completed
Trial end date:
2020-10-08
Target enrollment:
Participant gender:
Summary
This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the
virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age
(inclusive) who are close contacts of persons with laboratory confirmed SARS-CoV-2 or
clinically suspected COVID-19. Eligible participants will be enrolled and randomized to
receive the intervention or placebo at the level of the household (all eligible participants
in one household will receive the same intervention).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Washington
Collaborators:
Bill and Melinda Gates Foundation New York University